Massachusetts Institute of Technology in collaboration with University College London is announcing its 2017 Vaccines Bioprocess Development & Commercialization Workshop.

This three day workshop will explore the critical issues at the various stages of vaccine development. International experts with over 10 years’ experience in their field will lead delegates in developing their understanding in the research, operational and regulatory challenges of the vaccine market. In addition to expert lectures and excellent networking opportunities with your peers, one case study will be conducted during the workshop about manufacturing at-risk with real examples from the influenza manufacturing process.

 
top
Workshop Highlights

June 27
Speakers
Tarit Mukhopdhyay, University College London
Steven Hadley
,
Bill & Melinda Gates Foundation
Barry Buckland
,
previously Merck
Stacy L. Springs,
MIT
Derek O'Hagan,
GSK
Charles L. Cooney,
MIT

June 28
Speakers
Alain Pralong, previously GSK
Stephen A. Kolodziej, Pfizer, Inc.

Bob Sitrin, PATH
John Aunins, SERES
Martin Wisher, BioReliance
sanofi pasteur
Mathew Downham,
AstraZeneca

June 29
Keynote
Mark Feinberg, IAVI

Speakers
Tarit Mukhopadhyay, UCL
J. Christopher Love, MIT
Dan Barouch,
Harvard
Adrian Hill,
Oxford

Panel Discussion:
CMC Regulatory Challenges

Moderated by:
David Robinson,
previously Merck

Panel Members Include:
Robin Levis, FDA
Wim Van Molle, Scientific Institute of Public Health, Wetenschappelijk Instituut Volksgezondheid

 
bottom
 

This workshop is suitable for:

  • Scientists new to the vaccines sector (recent graduates / research scientists).
  • Scientists and technical managers who wish to broaden their knowledge in various vaccine technologies and platforms, exploring the interplay between process choices and regulation.
  • Project Managers, funders and policy-makers wanting to gain an understanding in vaccines.
 
Images
MIT CBI